The clinical impact of bronchoscopy: balancing microbiology and inflammatory endotyping Authors: Alessandro De Angelis, Edoardo Simonetta, Paola Scarano, Angela Tramontano, Mattia Nigro, Martina Lo Casto, Manuel Mancuso, Veronica Polelli, Salvatore Battaglia, Claudia Crimi, Oriol Sibila, James D. Chalmers, Francesco Blasi, Stefano Aliberti Published: 2026 ABSTRACT ExtractWe would like to thank L. Nguyen-Ho and Q-K. Tran-Le for their insightful comments on our study regarding the clinical impact of bronchoscopy in bronchiectasis management [1]. Their highlights regarding the potential role of bronchial lavage (BL) in inflammatory endotyping beyond microbiology are both timely and highly relevant. Reply to L. Nguyen-Ho and Q-K. Tran-Le: We would like to thank L. Nguyen-Ho and Q-K. Tran-Le for their insightful comments on our study regarding the clinical impact of bronchoscopy in bronchiectasis management [1]. Their highlights regarding the potential role of bronchial lavage (BL) in inflammatory endotyping beyond microbiology are both timely and highly relevant. As correctly noted by the authors, our research focused on the microbiological yield and subsequent “real-world” management changes. We believe that the strength of our study lies in its methodological consistency and pragmatic design. By employing a chest computed tomography-targeted approach to BL, we ensured that the samples were representative of the most affected lung segments; a precision that is often unattainable with spontaneous sputum, especially in “non-producers” or when samples are of poor quality. The suggestions regarding inflammatory markers, such as neutrophil elastase (NE) and differential cell counts, align perfectly with the emerging framework of “treatable traits” in airway diseases and bronchiectasis [2–4]. Identifying specific inflammatory endotypes, such as eosinophilic patterns, is indeed crucial for selecting patients who might benefit from targeted anti-inflammatory or biological therapies in the appropriate clinical context [5, 6]. However, it is important to note that type-2 directed biologics currently remain off-label for bronchiectasis; furthermore, a formal diagnosis of asthma or COPD is still required to consider adding inhaled corticosteroids, a therapy generally discouraged by current European guidelines [7]. Regarding NE, while its association with disease severity and exacerbation risk is supported by clinical evidence, there are currently no standardised clinical protocols for its measurement, and it is not yet recognised in international guidelines as a validated tool for routine monitoring or assessing treatment response [7, 8]. Furthermore, we agree that the integration of microbiological data with inflammatory profiling could significantly enhance our ability to predict and prevent exacerbations and improve quality of life [9, 10]. While our study demonstrated that bronchoscopy led to a management change in 51.1% of cases, primarily through targeted antibiotic adjustments and the exclusion of nontuberculous mycobacteria, the addition of biomarkers like BL-NE could provide a more comprehensive “lesion-specific” assessment of the risk for future lung function decline and frequency of exacerbations. Nevertheless, current clinical practice and international guidelines still base treatment indications primarily on the number of exacerbations, symptoms, quality of life and microbiology, rather than inflammatory profiles [7]. While we strongly believe in the future of pheno-endotyping, our study provides a pragmatic and safe assessment of the microbiological aspect, especially given that the role of BL remains only partially defined in the latest management guidelines. In conclusion, we advocate for a multidimensional approach where robust microbiological data and inflammatory endotyping coexist. This synergy represents the next frontier in achieving a truly personalized management of bronchiectasis.